نتایج جستجو برای: dlbcl
تعداد نتایج: 2906 فیلتر نتایج به سال:
Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoid malignancy. While a series of trials support R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus rituximab)-21 as the standard of care for all patients, DLBCL has substantial biological and clinical heterogeneity, leading to marked differences in outcomes for disease subgroups. We examine clinical...
Diffuse Large B-Cell Lymphomas (DLBCLs) are the most common histologic subtype within non-Hodgkin’s lymphomas (NHLs), accounting for approximately 30% of them. These lymphomas are a heterogeneous clinicopathologic entity characterized by marked phenotypic and clinical differences and several data indeed suggest that under the name of DLBCL different disease entities are currently included. This...
Purpose: There remains an unmet therapeutic need for patients with relapsed/refractory diffuse large Bcell lymphoma (DLBCL). The purpose of this study was to evaluate the therapeutic potential of sepantronium bromide (YM155), a survivin suppressant, in combination with either bendamustine or both bendamustine and rituximab using DLBCL models. Experimental Design: Human DLBCL cell lines, DB, SU-...
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults, accounting for 35%-40% of all cases. The combination of the anti-CD20 monoclonal antibody rituximab with anthracycline-based combination chemotherapy (R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) lead to complete remission in most and can cure more than half of patients with DLBCL. ...
Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of Non-Hodgkin’s lymphoma (NHL), accounting for approximately twenty five percent of cases. Forty percent of patients with DLBCL present with the primary lesion in an extranodal site. The gastrointestinal tract is the most frequent site of extranodal lymphoma, with the stomach and intestines most often involved. Involve...
CD37 (tetraspanin TSPAN26) is a B-cell surface antigen widely expressed on mature B cells. CD37 is involved in immune regulation and tumor suppression but its function has not been fully elucidated. We assessed CD37 expression in de novo diffuse large B-cell lymphoma (DLBCL), and investigated its clinical and biologic significance in 773 patients treated with rituximab plus cyclophosphamide, do...
Diffuse large B-cell lymphoma (DLBCL) is the most common canine aggressive B-cell lymphoma worldwide, and new recent molecular approaches have shown that DLBCL constitutes a heterogeneous tumor that cannot be unraveled by morphology and immunophenotype. DLBCL behaves aggressively, typically progressing over a short period of time, and the therapy response may be difficult to be predicted. Recen...
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous entity and the explicit mechanism of lymphomagenesis remains to be elucidated. CD40 ligand (CD40L, CD154) and interleukin-4 (IL-4) are important factors regulating B lymphocyte proliferation and differentiation; however, little is known about the effects of these factors on lymphomagenesis in DLBCL. In this study, we investigated the effe...
Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma in humans. The aggressive activated B cell-like (ABC) subtype of DLBCL is characterized by constitutive NF-kappaB activity and requires signals from CARD11, BCL10, and the paracaspase MALT1 for survival. CARD11, BCL10, and MALT1 are scaffold proteins that normally associate upon antigen receptor ligation. Signal-induced C...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in adults, characterized by a rapidly increasing painless mass. A novel compound, DCZ3301, was synthesized that exerted direct cytotoxicity against DLBCL cell lines. The effects of DCZ3301 on DLBCL cells in vitro and in vivo and the associated mechanisms were investigated. DCZ3301 inhibited the viability of DLBCL cell lin...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید